logo-loader
viewOpen Orphan PLC

Open Orphan: creating a valuable niche

Open Orphan (ORPH) presents an opportunity to invest in a company targeting value creation and rapid scale-up via acquisitions in the orphan and rare drugs market, which is growing at around 11% a year, around twice as fast as the global pharmaceuticals market. At the same time, there is a great disparity between the US and Europe in the number of orphan drugs on the market, which reflects an unmet need in the market for specialist services to help address the balance.

ORPH is addressing the opportunity within the pharma services market to create shareholder value by combining a number of smaller consultancies focused on the orphan and rare disease space, extracting both top-line and cost synergies. The company targets organic revenue growth as well as building critical mass from strategic acquisitions at favourable enterprise value/sales multiples.

Quick facts: Open Orphan PLC

Price: 6.55 GBX

AIM:ORPH
Market: AIM
Market Cap: £29.19 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Full interview: Open Orphan confirms hVIVO deal is done

Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. News here on the Genomic Database and how Friel expects hVIVO to make a profit. Confirmation too on the slight musical chairs within...

1 week, 2 days ago

RNS

Update on Placing

19 hours, 40 minutes ago

Holding(s) in Company

1 day, 16 hours ago

Holding(s) in Company

1 day, 16 hours ago

Holding(s) in Company

2 days, 12 hours ago

Holding(s) in Company

3 days, 10 hours ago

Euronext Growth Dublin Notice

3 days, 18 hours ago

27 min read